following a full submission:
dimethyl fumarate (Skilarence®) is accepted for restricted use within NHS Scotland.
Indication under review: for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
SMC restriction: for use in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate or have failed and who are considered unsuitable for biologic therapy given their current disease state or personal preference.
In a 16 week, double-blind, phase III study, dimethyl fumarate was superior to placebo and non-inferior to a fumaric acid ester product at improving the symptoms of moderate to severe plaque psoriasis in adults.
Download detailed advice236KB (PDF)
- Medicine name:
- dimethyl fumarate (Skilarence)
- SMC ID:
- Treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
- Pharmaceutical company
- Almirall Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full submission
- Date advice published:
- 09 April 2018